|1.||Hillmen, Peter: 19 articles (05/2014 - 02/2004)|
|2.||Risitano, Antonio M: 16 articles (09/2015 - 09/2006)|
|3.||Hill, Anita: 16 articles (09/2015 - 10/2005)|
|4.||Brodsky, Robert A: 15 articles (10/2014 - 09/2006)|
|5.||Rother, Russell P: 14 articles (08/2010 - 02/2004)|
|6.||Licht, Christoph: 9 articles (01/2016 - 09/2007)|
|7.||Schrezenmeier, Hubert: 9 articles (09/2015 - 09/2006)|
|8.||Socié, Gérard: 9 articles (09/2015 - 06/2008)|
|9.||Röth, Alexander: 7 articles (09/2015 - 09/2006)|
|10.||Muus, Petra: 7 articles (09/2015 - 09/2006)|
01/01/2008 - "Eculizumab is very effective in the treatment of intravascular hemolysis and all its sequelae, which include most of the symptoms and complications of PNH. "
03/27/2014 - "The anti-C5 antibody eculizumab has proven clinically effective, but uncontrolled C3 activation due to CD55 absence may result in opsonization of erythrocytes, possibly leading to clinically meaningful extravascular hemolysis. "
12/01/2013 - "The results of studies demonstrate that treatment with eculizumab alters the natural history of PNH by virtually eradicating thromboembolic complications, inhibiting of intravascular hemolysis and reducing or eliminating transfusion requirements. "
09/01/2015 - "Management of the classical form of PNH has been dramatically revolutionized by the development of eculizumab, which brings benefits in terms of hemolysis, quality of life, renal function, thrombotic risk, and life expectancy. "
07/01/2015 - "In vitro hemolysis due to non-mutant and mutant C5 was completely blocked by N19-8, a monoclonal antibody that binds to a different site on C5 than does eculizumab. "
|2.||Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria)
06/23/2011 - "Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival."
04/01/2012 - "The research discussed in this review describes development of eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and the efficacy of eculizumab on allergen-induced asthmatic responses in a placebo-controlled study. "
01/01/2013 - "Efficacy of eculizumab in a patient with paroxysmal nocturnal hemoglobinuria requiring transfusions 14 years after a diagnosis in childhood."
10/04/2006 - "[Evidence of the efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria]."
09/23/2015 - "Long Standing Eculizumab Treatment without Anticoagulant Therapy in High-Risk Thrombogenic Paroxysmal Nocturnal Hemoglobinuria."
06/01/2008 - "In the phase III, double-blind, placebo-controlled, TRIUMPH study, eculizumab reduced haemolysis, stabilized haemoglobin levels, reduced transfusion requirements and improved fatigue in patients with PNH. "
06/01/2008 - "Patients who required some transfusion support during treatment with eculizumab showed a reduction in haemolysis and transfusion requirements and an improvement in fatigue. "
12/03/2011 - "Eculizumab was also associated with significant improvements in fatigue and health-related quality-of-life scores in several trials. "
06/01/2008 - "Eculizumab reduces haemolysis and improves anaemia and fatigue, regardless of transfusion requirements."
07/01/2012 - "Eculizumab, an anti-C5 monoclonal antibody, is dramatically effective in controlling haemolysis and thrombosis, in reducing fatigue and in improving quality of life of patients. "
02/15/2008 - "Eculizumab treatment led to an improvement in anemia. "
01/01/2011 - "Twenty-seven of the 29 patients responded to eculizumab treatment, resulting in an 87% reduction in hemolysis (P < 0.0001) and subsequent improvement in anemia (P = 0.0003) despite reduction in transfusion requirements (P = 0.006). "
12/01/2011 - "Eculizumab has shown significant efficacy in controlled studies, with a marked decrease in anemia, fatigue, transfusion requirements, renal impairment, pulmonary hypertension, and risk of severe thromboembolic events, ultimately resulting in improving quality of life and survival."
01/01/2013 - "Eculizumab has been shown to improve anemia, decrease intravascular hemolysis, and reduce the risk of thrombosis. "
12/01/2010 - "These results show that eculizumab reduces the degree of intravascular hemolysis, reduces or eliminates the requirement of RBC transfusion, and improves anemia and fatigue in patients with PNH. "
10/01/2014 - "Sixteen patients have been treated with eculizumab so far in our series, and being a safe drug, it provides improvement in the patients' quality of life, and the disappearance of clinical symptoms, and avoids the emergence of new thrombosis."
08/01/2014 - "Taking these observations together, we suggest that the use of eculizumab be considered for treatment or prevention of arterial thrombosis complicated by PNH, although arterial thrombosis is an extremely rare event in the Japanese population. "
09/01/2013 - "The systemic complications typically associated with thrombosis were not observed for the following several months with early conservative treatments including eculizumab. "
01/01/2013 - "For these patients, eculizumab is a reasonable therapeutic option, expecting that by decreasing the risk for thrombosis, life expectancy may be increased. "
01/01/2013 - "Recent results demonstrated that eculizumab effectively reduces thrombosis. "
|1.||Complement System Proteins (Complement)
|2.||Atypical hemolytic uremic syndrome
|4.||Complement C5 (Complement 5)
|6.||Shiga Toxin (Shigella Toxin)
|7.||lenalidomide (CC 5013)
|8.||Azacitidine (5 Azacytidine)
|4.||Blood Transfusion (Blood Transfusions)
|5.||Homologous Transplantation (Allograft)